Corvus Pharma Com (CRVS) Stock Price, Quote & News

Company Profile

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psori...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 900 4520

Website: www.corvuspharma.com

Address:

901 Gateway Boulevard, Third Floor, South San Francisco, United States

lousjamsession Mar. 21 at 6:08 AM

$CRVS ......

0 · Reply

MomentumPulseTracker Mar. 21 at 5:17 AM

$CRVS biotech, just observing.

0 · Reply

DDtrader444 Mar. 21 at 3:26 AM

$CRVS just wait

0 · Reply

tradingjunk321 Mar. 21 at 1:41 AM

$CRVS Moore than before!

1 · Reply

Stackdoe101 Mar. 20 at 11:58 PM

$CRVS 🙃✨️

1 · Reply

DDtrader444 Mar. 20 at 8:06 PM

$CRVS and drop

1 · Reply

Jellysquid1 Mar. 20 at 7:47 PM

$CRVS The Selling is Drying Up! Long Term Investor!

2 · Reply

KingKai2020 Mar. 20 at 7:36 PM

$CRVS just hitting that mute button on the daily. so much easier.

0 · Reply

tradingjunk321 Mar. 20 at 7:32 PM

$CRVS we will get bought out by Large Pharma mark this post!

1 · Reply

tradingjunk321 Mar. 20 at 7:21 PM

$CRVS Super Bullish, but holy Fu** thank God they did offering at $22.15

2 · Reply

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript

Mar 12, 2026, 4:01 PM EDT - 8 days ago

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 5, 2026, 4:01 PM EST - 15 days ago

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Feb 23, 2026, 4:01 PM EST - 25 days ago

Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Jan 23, 2026, 5:00 PM EST - 2 months ago

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

Jan 21, 2026, 10:53 PM EST - 2 months ago

Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Jan 21, 2026, 2:50 PM EST - 2 months ago

Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon

Jan 21, 2026, 11:43 AM EST - 2 months ago

Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know

Jan 20, 2026, 5:15 PM EST - 2 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 Transcript

Jan 20, 2026, 4:01 PM EST - 2 months ago

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jan 20, 2026, 2:10 PM EST - 2 months ago

What made Corvus stock double on Tuesday and is it sustainable?

Jan 20, 2026, 2:00 PM EST - 2 months ago

Corvus Stock Spikes On Heels Of Strong Eczema Study Results

Jan 16, 2026, 4:01 PM EST - 2 months ago

Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Nov 4, 2025, 7:16 PM EST - 4 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:01 PM EST - 4 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results

Oct 31, 2025, 7:30 AM EDT - 5 months ago

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 28, 2025, 4:01 PM EDT - 5 months ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

Oct 17, 2025, 10:00 AM EDT - 5 months ago

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

Oct 2, 2025, 4:01 PM EDT - 6 months ago

Corvus Pharmaceuticals Appoints David Moore to Board of Directors

Aug 12, 2025, 11:31 PM EDT - 7 months ago

Corvus Pharmaceuticals: Positive Phase 1 Soquelitiinb Trial Data Brings 2025 Catalysts

Aug 8, 2025, 3:20 PM EDT - 8 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:01 PM EDT - 8 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

Jun 4, 2025, 7:00 AM EDT - 10 months ago

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

May 28, 2025, 4:01 PM EDT - 10 months ago

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 9, 2025, 11:57 AM EDT - 11 months ago

Why Is Corvus Pharmaceuticals Stock Soaring On Friday?

May 8, 2025, 11:06 PM EDT - 11 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:02 PM EDT - 11 months ago

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:01 PM EDT - 11 months ago

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Apr 23, 2025, 4:08 PM EDT - 11 months ago

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

Apr 9, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

Mar 28, 2025, 9:30 AM EDT - 1 year ago

Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials

Mar 28, 2025, 9:29 AM EDT - 1 year ago

Corvus Pharmaceuticals: Now At Cruising Altitude

Mar 25, 2025, 7:58 PM EDT - 1 year ago

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Mar 19, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 17, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

Feb 4, 2025, 8:00 AM EST - 1 year ago

Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 13, 2025, 7:30 AM EST - 1 year ago

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Jan 7, 2025, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 1:36 PM EST - 1 year ago

Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting

Dec 18, 2024, 1:23 PM EST - 1 year ago

Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?

Dec 18, 2024, 8:42 AM EST - 1 year ago

Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

HEI TSLA

Dec 18, 2024, 7:30 AM EST - 1 year ago

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Dec 17, 2024, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Dec 4, 2024, 4:05 PM EST - 1 year ago

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Nov 14, 2024, 10:01 AM EST - 1 year ago

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

Nov 13, 2024, 1:18 PM EST - 1 year ago

Corvus Pharmaceuticals: The Market Likes The Story

Nov 13, 2024, 12:02 AM EST - 1 year ago

Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript

lousjamsession Mar. 21 at 6:08 AM

$CRVS ......

0 · Reply

MomentumPulseTracker Mar. 21 at 5:17 AM

$CRVS biotech, just observing.

0 · Reply

DDtrader444 Mar. 21 at 3:26 AM

$CRVS just wait

0 · Reply

tradingjunk321 Mar. 21 at 1:41 AM

$CRVS Moore than before!

1 · Reply

Stackdoe101 Mar. 20 at 11:58 PM

$CRVS 🙃✨️

1 · Reply

DDtrader444 Mar. 20 at 8:06 PM

$CRVS and drop

1 · Reply

Jellysquid1 Mar. 20 at 7:47 PM

$CRVS The Selling is Drying Up! Long Term Investor!

2 · Reply

KingKai2020 Mar. 20 at 7:36 PM

$CRVS just hitting that mute button on the daily. so much easier.

0 · Reply

tradingjunk321 Mar. 20 at 7:32 PM

$CRVS we will get bought out by Large Pharma mark this post!

1 · Reply

tradingjunk321 Mar. 20 at 7:21 PM

$CRVS Super Bullish, but holy Fu** thank God they did offering at $22.15

2 · Reply

DDtrader444 Mar. 20 at 7:20 PM

$CRVS

0 · Reply

ObserverOne Mar. 20 at 7:16 PM

$CRVS phelps is back on x. It is impossible to escape the impression that it is related to the stock cratering.

1 · Reply

hmandude Mar. 20 at 7:07 PM

$CRVS What is this bullshit sigh

0 · Reply

DDtrader444 Mar. 20 at 6:52 PM

$CRVS dollar down a day keeps the doctor away🤷‍♂️

0 · Reply

kriscory69 Mar. 20 at 6:51 PM

$CRVS added again

1 · Reply

DDtrader444 Mar. 20 at 6:27 PM

$CRVS 👀🫣

1 · Reply

ILikeDaStocks Mar. 20 at 6:10 PM

$CRVS Past two months shorts have done well! However, shorting CRVS longterm may be financial suicide. And not talking years... Plenty of high-end data suggesting future of Soquelitinib is immense!! ↗️

0 · Reply

Dlhayes Mar. 20 at 4:57 PM

$CRVS The underwriters lead by Goldman and Jeffries have abandoned ship since the offering and have given control to the market makers who are feeding the short sellers. Meanwhile crickets from all the supporting analysts

0 · Reply

Jellysquid1 Mar. 20 at 4:33 PM

$CRVS These guys have Big skin in the Game! Top Investors in CRVS! Wouldn’t bet against them!

0 · Reply

Mr_Predicto Mar. 20 at 3:44 PM

$CRVS Jeez people. Not even a dead cat bounce? I have to admit I thought it would go lower, but not this fast. It's like a lead balloon. But hey, bright side, you can always DCA in at lower prices right? Prediction: Crystal ball please show us what happens if you continue to DCA in this stock.

1 · Reply

MedicalDoctorInvestor Mar. 20 at 3:13 PM

$CRVS will buy shares for $2.

1 · Reply

DDtrader444 Mar. 20 at 2:22 PM

$CRVS constant downtrend since pump…. I’m guessing probably $8 or $9 real soon before we see another pump

2 · Reply

Market Cap	1.18B
Revenue (ttm)	0.00
Net Income (ttm)	-15.28M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	4,926,200
Avg Vol	3,925,504
Day's Range	N/A - N/A
Shares Out	83.99M
Stochastic %K	9%
Beta	0.78
Analysts	Strong Sell
Price Target	$35.17